EHA 2026: Teclistamab Outcomes in High-Risk Extramedullary Myeloma
/ Astrid Hundebøll Torpe
EHA 2026: Circulating Tumor Plasma Cells Predict Progression in Smoldering Myeloma
/ Sigrun Thorsteinsdottir
EHA 2025: Real-World Insights on Belantamab Mafodotin in RRMM
/ Fredrik Schjesvold
Fredrik Schjesvold: Bridging Science and Clinical Innovation
/ Jan Andreasen
Advancing Myeloma Research and Treatment: An Interview with Fredrik Schjesvold
/ Fredrik Schjesvold / Jan Andreasen
Positive Outcome of Steroid Replacement in Transplant-Ineligible Myeloma
/ Frida Bugge Askeland











